Association between increased body mass index, calcineurin inhibitor use, and renal graft survival

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Objectives: Using data from the US Renal Data System, we examined the relation between body mass index and graft survival as mediated through calcineurin inhibitor use. Materials and Methods: Adult patients who received a first kidney-only transplant, with at least 6 months' survival were classified into 5 categories (underweight, normal, overweight, obese, and extremely obese) according to body mass index. Associations between calcineurin inhibitor use, body mass index categories, and outcomes were investigated. Results: Underweight and normal-weight recipients lived longer than the other 3 categories, regardless of calcineurin inhibitor use. Graft survival was significantly inferior among obese and extremely obese patients. Average graft survival was significantly higher for recipients with a normal body mass index than it was for overweight, obese, and extremely obese recipients. Risk ratio for graft failure was constant for the calcineurin inhibitor versus the noncalcineurin inhibitor group across all body mass index categories. Mean body mass index for the group with rejection episodes was similar to the group with no rejections; there was no correlation between body mass index and rejection risk. Conclusions: Increased body mass index is associated with inferior patient and graft survival, independent of calcineurin inhibitor use. Because we found no correlation between body mass index and risk of rejection, we assume that, at least after the initial 6 months, the adverse effect of obesity on graft outcome is partially mediated through nonimmunologic mechanisms. When analyzing graft and patient survival rates, we recommend that body mass index be considered a risk factor.

Original languageEnglish (US)
Pages (from-to)199-202
Number of pages4
JournalExperimental and Clinical Transplantation
Volume6
Issue number3
StatePublished - Sep 1 2008

Fingerprint

Graft Survival
Body Mass Index
Kidney
Thinness
Transplants
Calcineurin Inhibitors
Information Systems
Survival Rate
Obesity
Odds Ratio
Weights and Measures
Survival

All Science Journal Classification (ASJC) codes

  • Transplantation

Cite this

@article{797e4792e6cd4010b8e0370a2f108437,
title = "Association between increased body mass index, calcineurin inhibitor use, and renal graft survival",
abstract = "Objectives: Using data from the US Renal Data System, we examined the relation between body mass index and graft survival as mediated through calcineurin inhibitor use. Materials and Methods: Adult patients who received a first kidney-only transplant, with at least 6 months' survival were classified into 5 categories (underweight, normal, overweight, obese, and extremely obese) according to body mass index. Associations between calcineurin inhibitor use, body mass index categories, and outcomes were investigated. Results: Underweight and normal-weight recipients lived longer than the other 3 categories, regardless of calcineurin inhibitor use. Graft survival was significantly inferior among obese and extremely obese patients. Average graft survival was significantly higher for recipients with a normal body mass index than it was for overweight, obese, and extremely obese recipients. Risk ratio for graft failure was constant for the calcineurin inhibitor versus the noncalcineurin inhibitor group across all body mass index categories. Mean body mass index for the group with rejection episodes was similar to the group with no rejections; there was no correlation between body mass index and rejection risk. Conclusions: Increased body mass index is associated with inferior patient and graft survival, independent of calcineurin inhibitor use. Because we found no correlation between body mass index and risk of rejection, we assume that, at least after the initial 6 months, the adverse effect of obesity on graft outcome is partially mediated through nonimmunologic mechanisms. When analyzing graft and patient survival rates, we recommend that body mass index be considered a risk factor.",
author = "Nasrollah Ghahramani and {Brian Reeves}, W. and Hollenbeak, {Christopher S.}",
year = "2008",
month = "9",
day = "1",
language = "English (US)",
volume = "6",
pages = "199--202",
journal = "Experimental and Clinical Transplantation",
issn = "1544-1873",
publisher = "Cambridge University Press",
number = "3",

}

TY - JOUR

T1 - Association between increased body mass index, calcineurin inhibitor use, and renal graft survival

AU - Ghahramani, Nasrollah

AU - Brian Reeves, W.

AU - Hollenbeak, Christopher S.

PY - 2008/9/1

Y1 - 2008/9/1

N2 - Objectives: Using data from the US Renal Data System, we examined the relation between body mass index and graft survival as mediated through calcineurin inhibitor use. Materials and Methods: Adult patients who received a first kidney-only transplant, with at least 6 months' survival were classified into 5 categories (underweight, normal, overweight, obese, and extremely obese) according to body mass index. Associations between calcineurin inhibitor use, body mass index categories, and outcomes were investigated. Results: Underweight and normal-weight recipients lived longer than the other 3 categories, regardless of calcineurin inhibitor use. Graft survival was significantly inferior among obese and extremely obese patients. Average graft survival was significantly higher for recipients with a normal body mass index than it was for overweight, obese, and extremely obese recipients. Risk ratio for graft failure was constant for the calcineurin inhibitor versus the noncalcineurin inhibitor group across all body mass index categories. Mean body mass index for the group with rejection episodes was similar to the group with no rejections; there was no correlation between body mass index and rejection risk. Conclusions: Increased body mass index is associated with inferior patient and graft survival, independent of calcineurin inhibitor use. Because we found no correlation between body mass index and risk of rejection, we assume that, at least after the initial 6 months, the adverse effect of obesity on graft outcome is partially mediated through nonimmunologic mechanisms. When analyzing graft and patient survival rates, we recommend that body mass index be considered a risk factor.

AB - Objectives: Using data from the US Renal Data System, we examined the relation between body mass index and graft survival as mediated through calcineurin inhibitor use. Materials and Methods: Adult patients who received a first kidney-only transplant, with at least 6 months' survival were classified into 5 categories (underweight, normal, overweight, obese, and extremely obese) according to body mass index. Associations between calcineurin inhibitor use, body mass index categories, and outcomes were investigated. Results: Underweight and normal-weight recipients lived longer than the other 3 categories, regardless of calcineurin inhibitor use. Graft survival was significantly inferior among obese and extremely obese patients. Average graft survival was significantly higher for recipients with a normal body mass index than it was for overweight, obese, and extremely obese recipients. Risk ratio for graft failure was constant for the calcineurin inhibitor versus the noncalcineurin inhibitor group across all body mass index categories. Mean body mass index for the group with rejection episodes was similar to the group with no rejections; there was no correlation between body mass index and rejection risk. Conclusions: Increased body mass index is associated with inferior patient and graft survival, independent of calcineurin inhibitor use. Because we found no correlation between body mass index and risk of rejection, we assume that, at least after the initial 6 months, the adverse effect of obesity on graft outcome is partially mediated through nonimmunologic mechanisms. When analyzing graft and patient survival rates, we recommend that body mass index be considered a risk factor.

UR - http://www.scopus.com/inward/record.url?scp=58149291731&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149291731&partnerID=8YFLogxK

M3 - Article

C2 - 18954297

AN - SCOPUS:58149291731

VL - 6

SP - 199

EP - 202

JO - Experimental and Clinical Transplantation

JF - Experimental and Clinical Transplantation

SN - 1544-1873

IS - 3

ER -